Abstract
In November 2004, the very first issue of this journal featured articles on the pathogenesis of ulcerative colitis, mechanisms leading to chronic pancreatitis, and treatment of recurrent Clostridium-difficile-associated diarrhoea. Although those topics might seem familiar, much has changed in the intervening years in our understanding, diagnosis and treatment of many different diseases across the field of gastroenterology and hepatology. Nonetheless, many challenges remain. Here, we have asked five of our Advisory Board members—international experts across different subspecialties in gastroenterology and hepatology—to reflect on the progress and frustrations of the past 10 years. They also comment on where effort and money should be invested now, as well as their predictions for progress in the next 10 years.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pawlotsky, J. M. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 146, 1176–1192 (2014).
Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).
D'Ambrosio, R. et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 56, 532–543 (2012).
Marcellin, P. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381, 468–475 (2013).
Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179–185 (2012).
Vluggens, A. & Reddy, J. K. Nuclear receptors and transcription factors in the development of fatty liver disease. Curr. Drug Metab. 13, 1422–1435 (2012).
Takahashi, K., Yan, I., Wen, H. J. & Patel, T. MicroRNAs in liver disease: from diagnostics to therapeutics. Clin. Biochem. 46, 946–952 (2013).
Penton, A. L., Leonard, L. D. & Spinner, N. B. Notch signaling in human development and disease. Semin.Cell Dev. Biol. 23, 450–457 (2012).
Fraher, M. H., O'Toole, P. W. & Quigley, E. M. M. Techniques used to characterise the intestinal microbiota: a guide for the clinician. Nat. Rev. Gastroenterol. Hepatol. 9, 312–322 (2012).
Nicholson, J. K. et al. Host–gut microbiota metabolic interactions. Science 336, 1262–1267 (2012).
Cho, I. & Blaser, M. J. The human microbiome: at the interface of health and disease. Nat. Rev. Genet. 13, 260–270 (2012).
Cryan, J. F. & Dinan, T. G. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat. Rev. Neurosci. 13, 701–712 (2012).
Pawlotsky, J. M. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 146, 1176–1192 (2014).
Trépo, C., Chan, H. L. & Lok, A. Hepatitis B virus infection. Lancet http://dx.doi.org/10.1016/S0140-6736(14)60220-8.
Mayer, E. A. Gut feelings: the emerging biology of gut–brain communication. Nat. Rev. Neurosci. 12, 453–466 (2011).
Bravo, J. A. et al. Communication between gastrointestinal bacteria and the nervous system. Curr. Opin. Pharmacol. 12, 667–672 (2012).
De Palma, G., Collins, S. M., Bercik, P. & Verdu, E. F. The microbiota–gut–brain axis in gastrointestinal disorders: stressed bugs, stressed brain or both? J. Physiol. 592, 2989–2997 (2014).
Farmer, A. D., Randall, H. A. & Aziz, Q. It's a gut feeling: how the gut microbiota affects the state of mind. J. Physiol. 592, 2981–2988 (2014).
Ryan, K. K. et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509, 183–188 (2014).
Dockray, G. J. Gastrointestinal hormones and the dialogue between gut and brain. J. Physiol. 592, 2927–2941 (2014).
Coates, M. D. et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 126, 1657–1664 (2004).
Buhner, S. et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 137, 1425–1434 (2009).
Barbara, G. et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126, 693–702 (2004).
Labus, J. S. et al. Irritable bowel syndrome in female patients is associated with alterations in structural brain networks. Pain 155, 137–149 (2014).
Castro, J. et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3′, 5′-monophosphate. Gastroenterology 145, 1334–1346 (2013).
Manabe, N., Wong, B. S. & Camilleri, M. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders. Expert Opin. Investig. Drugs 19, 765–775 (2010).
Kurahashi, M. et al. A functional role for the 'fibroblast-like cells' in gastrointestinal smooth muscles. J. Physiol. 589, 697–710 (2011).
Gulbransen, B. D. & Sharkey, K. A. Novel functional roles for enteric glia in the gastrointestinal tract. Nat. Rev. Gastroenterol. Hepatol. 9, 625–632 (2012).
Matteoli, G. et al. A distinct vagal anti-inflammatory pathway modulates intestinal muscularis resident macrophages independent of the spleen. Gut 63, 938–948 (2013).
Costantini, T. W. et al. Vagal nerve stimulation protects against burn-induced intestinal injury through activation of enteric glia cells. Am. J. Physiol. Gastrointest. Liver Physiol. 299, G1308–G1318 (2010).
Nishiyama, C. et al. Trans-mesenteric neural crest cells are the principal source of the colonic enteric nervous system. Nat. Neurosci. 15, 1211–1218 (2012).
Laranjeira, C. et al. Glial cells in the mouse enteric nervous system can undergo neurogenesis in response to injury. J. Clin. Invest. 121, 3412–3424 (2011).
Won, K. J., Sanders, K. M. & Ward, S. M. Interstitial cells of Cajal mediate mechanosensitive responses in the stomach. Proc. Natl Acad. Sci. USA 102, 14913–14918 (2005).
Li, Z. et al. Essential roles of enteric neuronal serotonin in gastrointestinal motility and the development/survival of enteric dopaminergic neurons. J. Neurosci. 31, 8998–9009 (2011).
Yadav, V. K. et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135, 825–837 (2008).
Bischoff, S. C. et al. Role of serotonin in intestinal inflammation: knockout of serotonin reuptake transporter exacerbates 2,4,6-trinitrobenzene sulfonic acid colitis in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G685–G695 (2009).
Ghia, J. E. et al. Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology 137, 1649–1660 (2009).
Ellis, M., Chambers, J. D., Gwynne, R. M. & Bornstein, J. C. Serotonin and cholecystokinin mediate nutrient-induced segmentation in guinea pig small intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 304, G749–G761 (2013).
Huizinga, J. D. et al. The origin of segmentation motor activity in the intestine. Nat. Commun. 5, 3326 (2014).
Khoruts, A. et al. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile associated diarrhea. J. Clin. Gastroenterol. 44, 354–360 (2010).
Manichanh, C. et al. Reduced diversity of fecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 55, 205–211 (2006).
Sobhani, I. et al. Microbial dysbiosis in colorectal cancer patients. PLoS ONE 6, e16393 (2011).
Lee, K. et al. Altered intestinal microbiota in irritable bowel syndrome. Neurogastroenterol. Motil. 22, 493–498 (2010).
Kohli, A. et al. Treatment of Hepatitis C. A systematic review. JAMA 312, 631–640 (2014).
Lawitz, E. et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368, 1878–1887 (2013).
Poordad, F. et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N. Engl. J. Med. 370, 1973–1982 (2014).
Kabiri, M., Jazwinski, A. B., Roberts, M. S., Schaefer, A. J. & Chhatwal, J. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann. Intern. Med. 161, 170–180 (2014).
Shaheen, N. J. et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N. Engl. J. Med. 360, 2277–2288 (2009).
Pech, O. et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 146, 652–660 (2014).
Regueiro, M. et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 136, 441–450 (2009).
Schoen, R. E. et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N. Engl. J. Med. 366, 2345–2357 (2012).
Fink, S. P. et al. Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci. Transl. Med. 6, 233re2 (2014).
Rosendahl, J. et al. Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat. Genet. 40, 78–82 (2008).
Whitcomb, D. C. et al. Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis. Nat. Genet. 44, 1349–1354 (2012).
Witt, H. et al. Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat. Genet. 45, 1216–1220 (2013).
LaRusch, J. et al. Mechanisms of CFTR functional variants that impair regulated bicarbonate permeation and increase risk for pancreatitis but not for cystic fibrosis. PLoS Genet. 10, e1004376 (2014).
Talamini, G. et al. Smoking cessation at the clinical onset of chronic pancreatitis and risk of pancreatic calcifications. Pancreas 35, 320–326 (2007).
Yadav, D. et al. Alcohol consumption, cigarette smoking, and the risk of recurrent acute and chronic pancreatitis. Arch. Intern. Med. 169, 1035–1045 (2009).
Kisseleva, T., Gigante, E. & Brenner, D. A. Recent advances in liver stem cell therapy. Curr. Opin. Gastroenterol. 26, 395–402 (2010).
SFI Research Impact. Science Foundation Ireland [online], (2014).
Alimentary Pharmabiotic Centre[online], (2014).
Edwards, B. K. et al. Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 120, 1290–1314 (2014).
Festen, E. A. & Weersma, R. K. How will insights from genetics translate to clinical practice in inflammatory bowel disease? Best Pract. Res. Clin. Gastroenterol. 28, 387–397 (2014).
Bharucha, A. E. et al. American Gastroenterological Association technical review on constipation. Gastroenterology 144, 218–238 (2013).
Brandt, L. J. et al. American College of Gastroenterology Task Force on Irritable Bowel Syndrome: an evidence based position statement on the management of irritable bowel syndrome. Am. J. Gastroenterol. 104 (Suppl. 1), S1–S35 (2009).
Hazewinkel, Y. et al. Narrow-band imaging for the detection of polyps in patients with serrated polyposis syndrome: a multicenter, randomized, back-to-back trial. Gastrointest. Endosc. http://dx.doi.org/10.1016/j.gie.2014.06.043.
Omata, F. et al. Image-enhanced, chromo, and cap-assisted colonoscopy for improving adenoma/neoplasia detection rate: a systematic review and meta-analysis. Scand. J. Gastroenterol. 49, 222–237 (2014).
Dunbar, K. B. et al. Confocal laser endomicroscopy in Barrett's esophagus and endoscopically inapparent Barrett's neoplasia: a prospective randomized double-blind controlled crossover trial. Gastrointest. Endosc. 70, 645–654 (2009).
Kiesslich, R. et al. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology 132, 874–882 (2007).
Pasha, S. F. et al. Double-balloon enteroscopy and capsule endoscopy have comparable diagnostic yield in small-bowel disease: a meta-analysis. Clin. Gastroenterol. Hepatol. 6, 671–676 (2008).
Spada, C. et al. Second-generation colon capsule endoscopy compared with colonoscopy. Gastrointest. Endosc. 74, 581–589 (2011).
Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. U.S. Food and Drug Administration [online], (2004).
Barbosa, M. D. & Smith, D. D. Channeling postmarketing patient data into pharmaceutical regulatory systems. Drug Discov. Today http://dx.doi.org/10.1016/j.drudis.2014.07.011.
Moore, T. J. & Furberg, C. D. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008. JAMA Intern. Med. 174, 90–95 (2014).
Sacks, L. V. et al. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000–2012. JAMA 311, 378–384 (2014).
Heemstra, H. E. et al. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA. Drug Discov. Today 16, 73–80 (2011).
Juran, B. D. & Lazaridis, K. N. Genomics in the post-GWAS era. Semin. Liver Dis. 31, 215–222 (2011).
Claesson, M. J. et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 488, 178–184 (2012).
Cho, I. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 488, 621–626 (2012).
Turnbaugh, P. J. et al. A core gut microbiome in obese and lean twins. Nature 457, 480–484 (2009).
Parks, B. W. et al. Genetic control of obesity and gut microbiota composition in response to high-fat, high-sucrose diet in mice. Cell. Metab. 17, 141–152 (2013).
Karlsson, F. H. et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498, 99–103 (2013).
Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179–178 (2012).
Malfertheiner, P., Link, A. & Selgrad, M. Helicobacter pylori: perspectives and time trends. Nat. Rev. Gastroenterol. Hepatol. http://dx.doi.org/10.1038/nrgastro.2014.99.
Brenner, H., Stock, C. & Hoffmeister, M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ 348, 2467 (2014).
de Jonge, P. J., van Blankenstein, M., Grady, W. M. & Kuipers, E. J. Barrett's oesophagus: epidemiology, cancer risk and implications for management. Gut 63, 191–202 (2014).
Acknowledgements
S.L.F. performs laboratory studies supported by NIH grants DK56621 and AA020709. K.A.S. thanks G. Mawe, University of Vermont, USA, for his insightful comments and many helpful suggestions. K.A.S. holds the Crohn's & Colitis Foundation of Canada Chair in Inflammatory Bowel Disease Research. Owing to space limitations, only selected references were cited. J.J.Y.S. holds the Grants from the State Key Laboratory of People's Republic of China and Research Grant Committee of the Hong Kong SAR Government. D.C.W. thanks M. Kienholz, D. Yadav, and D. Conwell for critical review of the manuscript. D.C.W.'s research is supported by the NIH, the Department of Defense, the National Pancreas Foundation, and the Wayne Fusaro Pancreatic Cancer Research Fund, and an educational grant from AbbVie.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
S.L.F. acts as a consultant and has equity interests in Genfit and Intercept Pharmaceuticals. D.C.W. acts as a consultant for AbbVie, Millennium and Novartis and has equity in Ambry Genetics and SMART-MD. E.M.M.Q., K.A.S. and J.J.Y.S. declare no competing interests.
Rights and permissions
About this article
Cite this article
Friedman, S., Quigley, E., Sharkey, K. et al. The past 10 years of gastroenterology and hepatology—reflections and predictions. Nat Rev Gastroenterol Hepatol 11, 692–700 (2014). https://doi.org/10.1038/nrgastro.2014.167
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2014.167